Novo Nordisk’s Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Triggering global regulatory submissions this year for the treatment of obesity
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Delegates also visited Emami’s WHO-GMP-certified manufacturing plant and Zandu Foundation for Healthcare farms for hands-on exposure to quality practices,
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Subscribe To Our Newsletter & Stay Updated